For the quarter ended December 2025, Halozyme Therapeutics (HALO) reported revenue of $451.77 million, up 51.6% over the same period last year. EPS came in at -$0.24, compared to $1.26 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $448.62 million, representing a surprise of +0.7%. The company delivered an EPS surprise of -111.16%, with the consensus EPS estimate being $2.15.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $122.67 million versus $115.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +54.6% change.
- Revenues- Royalties: $257.97 million versus $262.14 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +51.4% change.
- Revenues- Revenues under collaboration agreements: $71.13 million compared to the $61.31 million average estimate based on four analysts. The reported number represents a change of +47.5% year over year.
View all Key Company Metrics for Halozyme Therapeutics here>>>
Shares of Halozyme Therapeutics have returned +11.6% over the past month versus the Zacks S&P 500 composite's -1.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
